A Comparative Study of 141 Glial Fibrillary Acidic Protein Immunoglobulin G Positive Cases.

Eur J Neurol

Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Published: March 2025

Background: Glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) positivity is associated with autoimmune GFAP astrocytopathy (GFAP-A), but also with other autoimmune encephalitides and viral infections. We attempted to elucidate the characteristics of GFAP-A in relation to other GFAP-IgG-positive encephalitides and constructed a differential diagnosis model.

Methods: 141 GFAP-IgG-positive cases were identified, including 52 astrocytopathy (GFAP-A group), 48 autoimmune encephalitis (AE-G), and 41 viral encephalitis (VE-G). Multivariate logistic regression was employed to create a diagnostic model, with validation using an external cohort.

Result: Compared to the AE-G group, the GFAP-A patients showed more onset age ≥ 50 years, headache, fever, consciousness disturbance, MRI radial vascular enhancement, cerebrospinal fluid (CSF) antibody titer grade ≥ 4, and CSF proteins ≥ 700 mg/L, but less female sex, limb numbness, visual disturbances, and CSF chloride ≤ 120 mmol/L. Among these, CSF antibody titer grade ≥ 4, CSF protein ≥ 700 mg/L, and absence of visual disturbances were independent risk factors for GFAP-A diagnosis. Compared to the VE-G group, the GFAP-A patients showed more course ≥ 14 days, onset age ≥ 50 years, limb weakness, serum potassium ≤ 3.9 mmol/L, CSF antibody titer grade ≥ 4, CSF leukocytes ≤ 46*10, MRI radial vascular enhancement, MRI involvement of brainstem, and MRI involvement of spinal cord, but less headache, fever, nausea, and vomiting. Among these, serum potassium ≤ 3.9 mmol/L, MRI spinal cord involvement, and absence of nausea and vomiting were independent risk factors for GFAP-A diagnosis.

Conclusions: Based on critical clinical indicators identified, we constructed a differential diagnosis model for GFAP-A.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886414PMC
http://dx.doi.org/10.1111/ene.70102DOI Listing

Publication Analysis

Top Keywords

csf antibody
12
antibody titer
12
titer grade
12
grade ≥ 4
12
≥ 4 csf
12
glial fibrillary
8
fibrillary acidic
8
gfap-a
8
astrocytopathy gfap-a
8
constructed differential
8

Similar Publications

Objective: The aim of this study was to analyze the clinical characteristics of adult patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis combined with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.

Methods: This was a non-randomized controlled study. Clinical data were collected from 17 patients with anti-NMDAR encephalitis combined with anti-MOG antibodies admitted to Xuanwu Hospital, Capital Medical University, from January 2020 to August 2024.

View Article and Find Full Text PDF

Cardiac fibrosis is a major driver of heart failure, a leading cause of morbidity and mortality worldwide. Advances in single-cell transcriptomics have revealed the pivotal role of SPP1+ macrophages in the pathogenesis of cardiac fibrosis, positioning them as critical mediators and promising therapeutic targets. SPP1+ macrophages, characterized by elevated expression of () and often co-expressing (), localize to fibrotic niches in the heart and other organs.

View Article and Find Full Text PDF

The diagnosis of Lyme neuroborreliosis (LNB) requires the demonstration of intrathecal synthesis of Borrelia antibodies in a patient's cerebrospinal fluid (CSF), which involves the invasive procedure of a lumbar puncture. This study serves as a feasibility study aimed at exploring the potential of using serum samples, which are easily obtainable routine clinical samples, for LNB diagnostics via advanced metabolomics techniques. Serum samples were collected from confirmed LNB patients before and after treatment, with post-treatment samples serving as controls.

View Article and Find Full Text PDF

Purpose: Naxitamab is a humanized form of the murine anti-GD2 monoclonal antibody (mAb) 3F8. In an international trial, naxitamab+GM-CSF was effective against chemo-resistant high-risk neuroblastoma (HR-NB), leading to approval by the Food and Drug Administration. We now report results with patients in 1st complete remission (CR).

View Article and Find Full Text PDF

Background: Shunt nephritis, although rare, should be high in the differential diagnoses for patients with gross or microscopic hematuria and a history of a ventriculoatrial/cystoatrial shunt.

Observations: The authors present the case of a 31-year-old female with a history of a resected posterior fossa hemangioblastoma and hydrocephalus, who presented to the nephrology clinic with night sweats and tea-colored urine for 3 months after being hospitalized for a saddle pulmonary embolism; kidney biopsy was contraindicated. The patient had hypocomplementemia, nephrotic-range proteinuria, positive proteinase 3-specific antineutrophil cytoplasmic antibody, and dysmorphic red blood cells in the urine sediment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!